HAYWARD, Calif., July 25, 2023 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, announced today that it will effect a 1-for-17 reverse stock split (“Reverse…Read More
Benitec Biopharma Inc Benitec Biopharma Announces 1for17 Reverse Stock Split Effective July 26 2023
